Lantheus Reaction Play: Shorting Into Regulatory Uncertainty After a PDUFA Extension
Lantheus (LNTH) faces a near-term tug-of-war: a valuable radiodiagnostics franchise and clean balance sheet versus compressed sales momentum for PYLARIFY and an apparent regulatory slip that extended a PDUFA timetable. The stock sits near $75.87 with a market cap around $4.9B and a P/E in the low-20s. For traders willing to accept elevated executio…